Delivery Order SPE2DR25D2104-SPE2DR26F3PEJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,710.27 to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg, a pharmaceutical product commonly used in treating inflammatory conditions. The award was made on November 12, 2025, with an ultimate completion date of November 13, 2025, under a firm fixed price contract type with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $16,991.63 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of September 15, 2025. The delivery order was issued on September 12, 2025, with performance to take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a $10,805.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg, a pharmaceutical product commonly used in the treatment of inflammatory conditions. The contract was competitively awarded with no set-aside designation and carries an ultimate completion date of July 24, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $11,650.04 to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg, a pharmaceutical product commonly used in treating autoimmune conditions. This firm fixed-price delivery order, issued on August 21, 2025, represents a non-competitive award under AmerisourceBergen's existing contract vehicle and is scheduled for completion by August 22, 2025. The product will be delivered to the company's corporate headquarters location in...
- The Defense Logistics Agency awarded a $35,178.29 delivery order to AmerisourceBergen Drug Corp for 60-count tablets of Otezla 30 mg, with a completion date of September 30, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a single delivery order fulfillment of the pharmaceutical product to support federal medical procurement needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $26,675.43 to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Otezla 30 mg tablets (60-count packaging). The contract represents a firm fixed price delivery order with an ultimate completion date of December 2, 2025, and was competitively awarded without any set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $16,643.64 to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on November 5, 2025, with completion scheduled for November 6, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued as a competitive award under the company's existing indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $17,620.78 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal contract portfolio. The product will be delivered to the company's corporate...
- The Defense Logistics Agency (DLA) awarded a $10,948.05 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, non-set-aside contract employs firm fixed-price pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The place of performance is listed as Conshohocken, Pennsylvania, which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Otezla 30 mg tablets (60-count) valued at $10,291.31 under a firm fixed-price contract. This competitive award, which carries no set-aside designation, represents a direct purchase order for this pharmaceutical product to support federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3PEJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,560.10 to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg, a pharmaceutical product used to treat inflammatory conditions. This non-set-aside, competitively awarded delivery order was executed on November 17, 2025, with an ultimate completion date of November 18, 2025, and operates under firm fixed-price terms. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This comprehensive IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including medications, vaccines, and medical devices across multiple therapeutic domains. The contract supports critical federal healthcare needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 11/17/25 |